An interventional study of Reprieve Decongestion Management System and Diuretic in Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular, Inc. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Reprieve Cardiovascular, Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,159 studies in Heart Failure with a site in United States, this one is the 647th largest by enrollment of the 1,602 interventional ones that give a count, is one of 107 that started in 2022, is one of 887 with no phase, and was the 1,642nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 313 · Phase 3 177 · Phase 4 139
First in 1983; this study’s year is marked. 107 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 1,602 interventional studies, 150 across the 552 observational. Of the 1,510 that completed or were terminated, 630 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
747 of 2,159 have an industry lead sponsor. The 10 most frequent:
Reprieve Cardiovascular, Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Reprieve Cardiovascular, Inc has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
138 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 138 to your calendar (.ics) → With an account.
Among the 2,159 studies in Heart Failure with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
Device: Reprieve Decongestion Management System
Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC) for patients randomized to control arm of the trial.
Drug: Diuretic
The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
Total Urine Sodium Output
Primary efficacy endpoint is total urine sodium output at 24 hours post-treatment initiation.
Time frame: 24 hours post-treatment initiation
Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency.
Primary safety endpoint includes clinically significant acute kidney injury defined as KDIGO stage 2 or greater AKI \[≥ doubling of baseline serum creatinine or use of renal replacement therapy (RRT)\], severe electrolyte abnormality (serum potassium \<3.0 mEq/L, magnesium \<1.3 mEq/L or sodium \<125 mEq), symptomatic hypotension or hypertensive emergency.
Time frame: End of treatment, 0-72 hours.
Net Fluid Loss
Difference in the amount of net fluid removed during primary treatment
Time frame: End of treatment, 0-72 hours
Time on IV Loop Diuretics
Time from initiation of IV loop diuretics to discontinuation of IV loop diuretics
Time frame: 0 hours (treatment initiation) through hospital discharge, up to 1-2 weeks
2,216 patients were screened between July 2022 and October 2024 at 16 hospitals in the United States.
| Milestone | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Started | 56 | 44 |
| Completed | 52 | 44 |
| Not completed | 4 | 0 |
| Withdrew: Unable to pass urinary catheter | 4 | 0 |
Primary efficacy endpoint is total urine sodium output at 24 hours post-treatment initiation.
| mmol of sodium | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Total Urine Sodium Output | 1082 ± 487 | 423 ± 290 |
Primary safety endpoint includes clinically significant acute kidney injury defined as KDIGO stage 2 or greater AKI \[≥ doubling of baseline serum creatinine or use of renal replacement therapy (RRT)\], severe electrolyte abnormality (serum potassium \<3.0 mEq/L, magnesium \<1.3 mEq/L or sodium \<125 mEq), symptomatic hypotension or hypertensive emergency.
| total number of events | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency. | 16 | 19 |
Difference in the amount of net fluid removed during primary treatment
| liters | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Net Fluid Loss | 8.1 ± 5.7 | 8.1 ± 7.1 |
Time from initiation of IV loop diuretics to discontinuation of IV loop diuretics
| hours | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Time on IV Loop Diuretics | 46 (29 to 80) | 88 (44 to 143) |
Collected over From enrollment until end of follow up, up to 90 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reprieve Decongestion Management System | 3/52 (5.8%) | 29/52 (55.8%) | 44/52 (84.6%) |
| Optimal Diuretic Therapy | 3/44 (6.8%) | 23/44 (52.3%) | 35/44 (79.5%) |
| Event | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Cardiac disorderCardiac disorders | 17/52 | 15/44 |
| Infectious disordersInfections and infestations | 10/52 | 7/44 |
| Renal and urinary disordersRenal and urinary disorders | 6/52 | 8/44 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 5/52 | 6/44 |
| Vascular disordersVascular disorders | 6/52 | 4/44 |
| Administration site disordersSkin and subcutaneous tissue disorders | 2/52 | 4/44 |
| Respiratory, thoracic, and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 2/52 | 4/44 |
| Falls and limb injury disordersInjury, poisoning and procedural complications | 3/52 | 0/44 |
| Psychiatric disordersPsychiatric disorders | 0/52 | 2/44 |
| Nervous system disordersNervous system disorders | 2/52 | 1/44 |
| Event | Reprieve Decongestion Management System | Optimal Diuretic Therapy |
|---|---|---|
| Electrolyte and fluid disordersGeneral disorders | 27/52 | 19/44 |
| Renal and urinary disordersRenal and urinary disorders | 6/52 | 7/44 |
| Vascular disorderVascular disorders | 5/52 | 1/44 |
| Cardiac disorderCardiac disorders | 1/52 | 4/44 |
| Electrolyte disorderGeneral disorders | 3/52 | 0/44 |
| Other disordersGeneral disorders | 2/52 | 2/44 |
| Catheter-associated UTIInfections and infestations | 1/52 | 2/44 |
| Psychiatric disordersPsychiatric disorders | 0/52 | 1/44 |
| Musculoskeletal disorderMusculoskeletal and connective tissue disorders | 1/52 | 1/44 |
| Administration site disordersGeneral disorders | 1/52 | 0/44 |
| Age, Continuous(years) | Reprieve Decongestion Management System | Optimal Diuretic Therapy | Total |
|---|---|---|---|
| Mean | 64 ± 13 | 63 ± 14 | 63 ± 14 |
| Sex: Female, Male(Participants) | Reprieve Decongestion Management System | Optimal Diuretic Therapy | Total |
|---|---|---|---|
| Female | 23 | 20 | 43 |
| Male | 29 | 24 | 53 |
| Race/Ethnicity, Customized(Participants) | Reprieve Decongestion Management System | Optimal Diuretic Therapy | Total |
|---|---|---|---|
| White | 31 | 26 | 57 |
| Black | 18 | 18 | 36 |
| Other | 3 | 0 | 3 |
| Serum creatinine(mg/dL) | Reprieve Decongestion Management System | Optimal Diuretic Therapy | Total |
|---|---|---|---|
| Mean | 1.48 ± 0.56 | 1.44 ± 0.56 | 1.46 ± 0.62 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2022 to primary completion in Jan 2025, 29 months.
Results were first posted in May 2026, 1 year 4 months after primary completion.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 29 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reprieve Cardiovascular, Inc